Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  angiogenesis inhibitor
Results 1-25 of 1966 for your search:
Start Over
Paclitaxel and Vascular-Targeting Gene Therapeutic VB-111 in Treating Patients with Recurrent Uterine, Ovarian, and Fallopian Tube Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 19
Trial IDs: 11-418, NCI-2013-00628, NCT01801215, VB-111-157, NCT01711970
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-215, NCI-2015-01344, NCT02511405
TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients with Advanced EGFR Mutation Positive Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PJC-020, NCI-2015-01139, 9910, 9910/PJC-020, NCT02503722
Topoisomerase I Inhibitor LMP400 and Topoisomerase I Inhibitor LMP776 in Treating Patients with Relapsed Solid Tumors or Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0056, NCI-2011-02515, 100056, CDR0000662682, NCT01245192, P08394, 8273, NCT01051635
Olaparib and mTOR Kinase Inhibitor AZD2014 or AKT Inhibitor AZD5363 in Treating Patients with Recurrent Endometrial, Triple Negative Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0784, NCI-2014-01973, NCT02208375
PI3K Inhibitor BKM120 or PI3K Inhibitor BYL719 and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-159, NCI-2012-01929, NCT01623349
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: P1446A-05/72/12, NCI-2013-02011, NCT01841463
ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-001, NCI-2014-00263, NCT02029443
TORC1/2 Inhibitor INK128 before and after Surgery in Treating Patients with Recurrent Glioblastoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ABTC-1301, NCI-2014-00907, 1301, NCT02133183
TORC1/2 Inhibitor MLN0128 in Treating Patients with Stage IV or Recurrent Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9780, NCI-2015-00545, 2015-00500, NCT02417701
TORC1/2 Inhibitor INK128 in Treating Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1482, NCI-2015-01000, 9775, NCT02484430
MDM2 Inhibitor DS-3032b in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0101, NCI-2015-01873, NCT02579824
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients with Progressive Meningiomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071401, NCI-2015-00546, NCI-2015-00501, NCT02523014
EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients with EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PhI-77, NCI-2015-01053, 9898, NCT02496663
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: P7170/70/11, NCI-2013-00315, NCT01762410
C-met Inhibitor INCB028060 in Treating Patients with Papillary Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0037, NCI-2014-02464, 09-25-0099, 140037, 340263, P131324, NCT02019693
PI3K Inhibitor BKM120 and Everolimus in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WCI1925-10, NCI-2012-00210, IRB00048549, NCT01470209
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2076-CL-005, NCI-2013-00059, NCT01639248
PI3K inhibitor BKM120 in Treating Patients With High-Risk, Localized Prostate Cancer Undergoing Surgery
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: 115516, NCI-2013-01830, CBKM120ZUS26T, UCSF CC# 115516, NCT01695473
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: PL225B/71/11, NCI-2013-01024, NCT01779336
HSP90 Inhibitor AUY922 in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-484, NCI-2013-01819, NCT01854034
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16447, NCI-2014-00484, 2012-004671-39, NCT01915576
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CX-839-001, NCI-2014-01059, NCT02071862
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CX-839-002, NCI-2014-02615, NCT02071888
Start Over